headquartered in lexington, ma, ispecimen is the marketplace for human biospecimens, providing researchers with the specimens they need from the patients they want. the privately held company has developed the ispecimen marketplace, an online platform connecting healthcare organizations that have access to patients and specimens with the scientists who need them. proprietary, cloud-based technology enables researchers to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. researchers easily and compliantly gain access to specimens to drive scientific discovery. partner sites gain an opportunity to contribute to biomedical discovery as well as their bottom line. and ultimately, healthcare advances for all.
Company profile
Ticker
ISPC
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Syneos Health • Icon • Medpace • Incyte • Zymergen • OmniAb ...
SEC CIK
Corporate docs
IRS number
270480143
ISPC stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
26 Mar 24
8-K
Results of Operations and Financial Condition
14 Mar 24
10-K
2023 FY
Annual report
13 Mar 24
8-K
Entry into a Material Definitive Agreement
5 Mar 24
424B5
Prospectus supplement for primary offering
5 Mar 24
8-K
Entry into a Material Definitive Agreement
15 Feb 24
8-K
Departure of Directors or Certain Officers
21 Dec 23
8-K
Results of Operations and Financial Condition
2 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Results of Operations and Financial Condition
23 Oct 23
Transcripts
ISPC
Earnings call transcript
2023 Q3
2 Nov 23
ISPC
Earnings call transcript
2023 Q2
2 Aug 23
ISPC
Earnings call transcript
2023 Q1
4 May 23
ISPC
Earnings call transcript
2023 Q1
4 May 23
ISPC
Earnings call transcript
2022 Q4
14 Mar 23
ISPC
Earnings call transcript
2022 Q3
8 Nov 22
ISPC
Earnings call transcript
2022 Q2
8 Aug 22
ISPC
Earnings call transcript
2022 Q1
14 May 22
ISPC
Earnings call transcript
2021 Q4
17 Feb 22
ISPC
Earnings call transcript
2021 Q3
6 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.72 mm | 2.72 mm | 2.72 mm | 2.72 mm | 2.72 mm | 2.72 mm |
Cash burn (monthly) | (no burn) | 1.49 mm | 731.36 k | 870.00 k | 544.59 k | 530.00 k |
Cash used (since last report) | n/a | 8.89 mm | 4.35 mm | 5.17 mm | 3.24 mm | 3.15 mm |
Cash remaining | n/a | -6.17 mm | -1.63 mm | -2.45 mm | -516.51 k | -429.77 k |
Runway (months of cash) | n/a | -4.1 | -2.2 | -2.8 | -0.9 | -0.8 |
Institutional ownership, Q2 2023
18.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 14 |
Opened positions | 2 |
Closed positions | 4 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 575.82 mm |
Total shares | 1.70 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
OBF Investments | 841.98 k | $0.00 |
Empery Asset Management | 437.50 k | $0.00 |
Vanguard | 162.90 k | $232.95 mm |
Grimes & Company | 65.59 k | $93.79 mm |
BLK Blackrock | 56.70 k | $81.08 mm |
Citadel Advisors | 23.17 k | $33.14 mm |
Geode Capital Management | 21.60 k | $30.88 mm |
Schonfeld Strategic Advisors | 20.20 k | $28.89 mm |
Claro Advisors | 17.31 k | $24.75 mm |
Renaissance Technologies | 14.90 k | $21.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Sep 23 | Benjamin Bielak | Common Stock | Buy | Acquire P | No | No | 0.72 | 18,000 | 12.96 k | 84,348 |
31 May 23 | Tracy Curley | Common Stock | Buy | Acquire P | No | No | 1.25 | 4,400 | 5.50 k | 49,541 |
17 Jan 23 | Jill Mullan | Common Stock | Option exercise | Acquire M | No | No | 1 | 66,637 | 66.64 k | 246,226 |
17 Jan 23 | Jill Mullan | Option Common Stock | Option exercise | Dispose M | No | No | 1 | 66,637 | 66.64 k | 10,000 |
3 Jan 23 | Andrew L. Ross | Option Common Stock | Grant | Acquire A | No | No | 1.41 | 10,000 | 14.10 k | 23,525 |
News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
26 Mar 24
12 Health Care Stocks Moving In Thursday's Intraday Session
14 Mar 24
iSpecimen: Q4 Earnings Insights
13 Mar 24
iSpecimen Q4 2023 GAAP EPS $(0.34) Misses $(0.24) Estimate, Sales $2.575M Miss $3.041M Estimate
13 Mar 24
Earnings Scheduled For March 13, 2024
13 Mar 24
Press releases
iSpecimen Reschedules Full Year 2023 Earnings Release and Conference Call
12 Mar 24
iSpecimen and TriMetis Life Sciences Announce Strategic Partnership to Help Transform Tissue-Based Research
23 Jan 24
iSpecimen to Participate in Maxim Group Healthcare IT Virtual Conference, January 24 & 25, 2024
18 Jan 24